Aytu BioPharma Past Earnings Performance
Past criteria checks 0/6
Aytu BioPharma's earnings have been declining at an average annual rate of -10.8%, while the Pharmaceuticals industry saw earnings declining at 0.9% annually. Revenues have been growing at an average rate of 36.8% per year.
Key information
-10.8%
Earnings growth rate
69.3%
EPS growth rate
| Pharmaceuticals Industry Growth | 14.1% |
| Revenue growth rate | 36.8% |
| Return on equity | -44.5% |
| Net Margin | -14.6% |
| Last Earnings Update | 31 Mar 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Aytu BioPharma makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 24 | 94 | -14 | 52 | 2 |
| 31 Dec 23 | 98 | -18 | 60 | 2 |
| 30 Sep 23 | 102 | -24 | 67 | 4 |
| 30 Jun 23 | 107 | -17 | 70 | 4 |
| 31 Mar 23 | 104 | -32 | 73 | 9 |
| 31 Dec 22 | 106 | -77 | 71 | 9 |
| 30 Sep 22 | 102 | -82 | 70 | 12 |
| 30 Jun 22 | 97 | -109 | 70 | 13 |
| 31 Mar 22 | 93 | -112 | 73 | 14 |
| 31 Dec 21 | 82 | -84 | 68 | 11 |
| 30 Sep 21 | 74 | -82 | 62 | 7 |
| 30 Jun 21 | 66 | -58 | 56 | 6 |
| 31 Mar 21 | 57 | -42 | 47 | 2 |
| 31 Dec 20 | 52 | -22 | 42 | 2 |
| 30 Sep 20 | 40 | -13 | 37 | 2 |
| 30 Jun 20 | 28 | -14 | 31 | 2 |
| 31 Mar 20 | 14 | -25 | 24 | 0 |
| 31 Dec 19 | 9 | -24 | 22 | 0 |
| 30 Sep 19 | 7 | -29 | 21 | 1 |
| 30 Jun 19 | 7 | -27 | 19 | 1 |
| 31 Mar 19 | 7 | -12 | 18 | 1 |
| 31 Dec 18 | 5 | -10 | 18 | 1 |
| 30 Sep 18 | 4 | -9 | 17 | 0 |
| 30 Jun 18 | 4 | -10 | 18 | 0 |
| 31 Mar 18 | 4 | -17 | 17 | 0 |
| 31 Dec 17 | 4 | -20 | 17 | 1 |
| 30 Sep 17 | 4 | -21 | 16 | 1 |
| 30 Jun 17 | 3 | -23 | 17 | 1 |
| 31 Mar 17 | 3 | -31 | 17 | 4 |
| 31 Dec 16 | 3 | -33 | 15 | 5 |
| 30 Sep 16 | 3 | -32 | 13 | 6 |
| 30 Jun 16 | 3 | -28 | 9 | 6 |
| 31 Mar 16 | 2 | -15 | 7 | 4 |
| 31 Dec 15 | 1 | -10 | 6 | 4 |
| 30 Sep 15 | 1 | -8 | 5 | 3 |
| 30 Jun 15 | 0 | -8 | 4 | 3 |
| 31 Mar 15 | 0 | -7 | 4 | 4 |
| 31 Dec 14 | 0 | -7 | 3 | 4 |
| 30 Jun 14 | 0 | -6 | 2 | 4 |
| 31 Dec 13 | 0 | -4 | 2 | 3 |
| 30 Jun 13 | 0 | -3 | 1 | 3 |
Quality Earnings: 0A8M is currently unprofitable.
Growing Profit Margin: 0A8M is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 0A8M is unprofitable, and losses have increased over the past 5 years at a rate of 10.8% per year.
Accelerating Growth: Unable to compare 0A8M's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 0A8M is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (1.2%).
Return on Equity
High ROE: 0A8M has a negative Return on Equity (-44.46%), as it is currently unprofitable.